Research programme: MNK1/MNK2 inhibitors - SelvitaAlternative Names: MKNK1/MKNK2 protein inhibitors; MNK1/2 kinase inhibitors - Selvita; SEL201
Latest Information Update: 10 Nov 2015
At a glance
- Originator Selvita
- Class Small molecules
- Mechanism of Action MKNK1 protein inhibitors; MKNK2 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 01 Nov 2015 Preclinical trials in Cancer in Poland (unspecified route)
- 11 Nov 2014 Early research in Cancer in Poland (unspecified route)